Vidhyalakshmi Kannan, MD
Endocrinology, Diabetes & Metabolism · Mesa, AZNPI 1275724452
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,277 of the $110,638 with a category attached, or 68.0%. 58 manufacturers reported payments, led by Corcept Therapeutics at 43.0% of the total. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,435 payments — averaging $77.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$48K
- Boehringer Ingelheim$23K
- Lilly USA, LLC$22K
- Medtronic$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- plus $13K from 52 others
What the payments were for
- Consulting fees$3,8503%
- Speaking & faculty fees$75,27768%
- Travel & lodging$5,8895%
- Food & beverage$25,46523%
- Education$980%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$110,638 in reported general payments places this provider in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 21 | $422,597 |
| OzempicSemaglutide | 146 | $276,410 |
| TrulicityDulaglutide | 147 | $256,691 |
| JardianceEmpagliflozin | 165 | $238,895 |
| MounjaroTirzepatide | 82 | $135,562 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 73 | $86,292 |
| Tresiba Flextouch U-100Insulin Degludec | 63 | $66,667 |
| FiaspInsulin Aspart (Niacinamide) | 50 | $65,827 |
| ForteoTeriparatide | 15 | $64,294 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 43 | $53,121 |
| Novolog FlexpenInsulin Aspart | 105 | $48,751 |
| JanuviaSitagliptin Phosphate | 30 | $44,583 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $44,431 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $36,984 |
| OmnitropeSomatropin | 14 | $35,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog, Insulin Lispro | $21,762 | $479,712345 claims |
| Corcept TherapeuticsKorlym | $47,622 | $422,59721 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $1,687 | $356,771231 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $22,850 | $284,047199 claims |
| MerckJanuvia | $302 | $44,58330 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $985 | $42,82077 claims |
| AstraZenecaFarxiga | $1,724 | $31,36725 claims |
| AmgenProlia | $811 | $27,77916 claims |
| AbbVieSynthroid | $645 | $9,85697 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $372 | $8,520820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Mesa
- Gyan BrardMesa$12K
- Shahzad ShadmanyMesa$9K
- Roberta EscaleraMesa$5K
- Muhammad SethiTucson$670K
- Kevin YuenPhoenix$404K
- Amir HarariScottsdale$361K
- Joan BaileyPhoenix$316K
- Kristina BlohmScottsdale$220K
- Karen HerbstTucson$200K
- Laura KnechtCave Creek$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.